RxDoctor Payments Data

Rene Perez Rios, MD

Cardiovascular Disease · Bayamon, PRNPI 1053329532

Payments from drug & device makers

$1,323in general payments, 2019–2025

Across 56 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$184
  • AstraZeneca$162
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$152
  • Johnson & Johnson$149
  • E.r. Squibb & Sons, L.L.C.$140
  • Medtronic$140
  • plus $396 from 8 others

What the payments were for

  • Food & beverage$1,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific6$184
AstraZeneca9$162
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)9$152
Johnson & Johnson6$149
E.r. Squibb & Sons, L.L.C.3$140
Medtronic(2 entities)7$140
Abbott5$97
Chiesi USA, Inc.1$91
Amgen3$63
PBG Puerto Rico LLC3$61
Acist Medical Systems, Inc.1$31
Novartis1$25
Terumo Medical Corporation1$14
Cardinal Health P.r. 120 Inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,323 in reported general payments places this provider in the 30th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$55,496
Medicare patients
87
Services billed
361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor224$124,721
XareltoRivaroxaban47$30,124
EliquisApixaban17$19,368
JanuviaSitagliptin Phosphate11$4,795
Ezetimibe195$3,027
SynthroidLevothyroxine Sodium29$2,275
Atorvastatin Calcium204$2,090
Colchicine35$1,190
Candesartan Cilexetil14$1,104
ClopidogrelClopidogrel Bisulfate75$1,000
Prasugrel Hcl22$846
Isosorbide Mononitrate ErIsosorbide Mononitrate64$710
Doxazosin Mesylate24$682
Rosuvastatin Calcium36$509
Metoprolol Succinate49$491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$162$124,721224 claims
Johnson & JohnsonXarelto$149$30,12447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →